Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Other

Could Evkeeza’s New Peds Approval Result in a PRV for REGN?

Here is a brief preview of this blast: Regeneron announced FDA has accepted the Evkeeza (evinacumab) sBLA for the treatment of homozygous familial hypercholesterolemia (HoFH) in children ages 5 to 11 with a PDUFA date of March 30, 2023. Recall, in February 2021, Evkeeza received FDA approval for the treatment of HoFH in patients 12 years of age and older (previous FENIX insight). Below, FENIX wonders if the approval could result in a PRV.